Liver Cancer Medications

Here's a list of the approved drugs to treat liver cancer. Click on any of the medications for more info on indications, dosing and side effects.

Quick Links

Chemotherapy Medications
Immunotherapy Medications
Targeted Therapy Medications

Quick Filter

*generic version available

E experimental

Chemotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Chemotherapy	Multiple	Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Immunotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Keytruda	pembrolizumab	Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.
Opdivo	nivolumab	Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.
Tecentriq	atezolizumab	Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, metastatic liver cancer and inoperable or metastatic melanoma.

Targeted Therapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Avastin	bevacizumab	Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.
Cabometyx	cabozantinib	Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).
Cyramza	ramucirumab	Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.
Lenvima	lenvatinib	Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.
Nexavar	sorafenib	Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.
Rozlytrek	entrectinib	Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.
Stivarga	regorafenib	Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).
Vitrakvi	larotrectinib	Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

Chemotherapy Medications More >>

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Immunotherapy Medications More >>

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.

DRUG Keytruda

GENERIC NAME pembrolizumab

DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Opdivo

GENERIC NAME nivolumab

DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Tecentriq
GENERIC NAME atezolizumab
DRUG INDICATION Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, metastatic liver cancer and inoperable or metastatic melanoma.

Targeted Therapy Medications More >>

DRUG Avastin
GENERIC NAME bevacizumab
DRUG INDICATION Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

DRUG Cabometyx
GENERIC NAME cabozantinib
DRUG INDICATION Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

DRUG Cyramza
GENERIC NAME ramucirumab
DRUG INDICATION Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

DRUG Lenvima
GENERIC NAME lenvatinib
DRUG INDICATION Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

DRUG Nexavar
GENERIC NAME sorafenib
DRUG INDICATION Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Stivarga
GENERIC NAME regorafenib
DRUG INDICATION Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).